T-Rex 2X Long MSTR Daily Target ETF vs TransMedics Group Inc — how do they compare? T-Rex 2X Long MSTR Daily Target ETF trades at $39.94 (market cap $809.00M), while TransMedics Group Inc trades at $78.15 (market cap $2.74B). The key difference: TransMedics Group Inc is far larger — about 3.4× T-Rex 2X Long MSTR Daily Target ETF's market cap, and TransMedics Group Inc is trading nearer its 52-week high, T-Rex 2X Long MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Long MSTR Daily Target ETF for 18 Days and TransMedics Group Inc for 24 Days on average.
| MSTU | TMDX | |
|---|---|---|
Market Cap | $809.00M | $2.74B |
Volume | 4,577,465 | 949,331 |
Sector | Leveraged / Inverse | Health |
52-Week High | $451.00 | $150.42 |
52-Week Low | $14.60 | $61.99 |
Typical Hold Time | 18 Days | 24 Days |
Enterprise Value | — | $3.13B |
Signals from Pluang's Aura AI — not financial advice
MSTU trades at $40.50, up 2.66% with a bearish technical signal from moving averages while oscillators remain neutral. The stock faces significant resistance at $41-$43 levels with support at $37-$35. Recent corporate actions include a 10:1 reverse stock split effective August 24, 2026, and a $0.29 dividend declaration for H2-2026.
The leveraged ETF structure presents both opportunity and risk - offering amplified exposure to MSTR but with daily rebalancing that can erode value during volatility. Key risks include the compounding effect of daily leverage and Bitcoin price sensitivity. Investors should monitor the underlying stock's fundamentals and Bitcoin market dynamics closely.
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
MSTU is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bullish (long) position in MSTR, a company known for its significant Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on MSTU →TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →